The 60 references in paper S. Avdeev N., С. Авдеев Н. (2014) “Новые возможности использования тиотропия бромида с помощью аэрозольного устройства доставки – ингалятора Респимат® // New abilities of administration of tiotropium bromide using the aerosol delivery device Respimat®” / spz:neicon:pulmonology:y:2013:i:5:p:70-80

1
Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2013 report is available on www.goldcopd.com
(check this in PDF content)
2
Celli B.R., MacNee W.; ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.
(check this in PDF content)
3
Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.
(check this in PDF content)
4
Panning C.A., DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183–189.
(check this in PDF content)
5
Yohannes A.M., Connolly M., Hanania N.A.Ten years of tiotropium: clinical impact and patient perspectives. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 117–125.
(check this in PDF content)
6
Tashkin D.P. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr. Opin. Pulm. Med. 2010; 16: 97–105.
(check this in PDF content)
7
Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
(check this in PDF content)
8
Vincken W., van Noord J.A., Greefhorst A.P.M. et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotopium. Eur. Respir. J. 2002; 19: 209–216.
(check this in PDF content)
9
Casaburi R., Mahler D.A., Jones P.W. et al.A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 1: 217–224.
(check this in PDF content)
10
Brusasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404.
(check this in PDF content)
11
Celli B., Wallack R.Z., Wang S. et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;
(check this in PDF content)
12
1743–1748. 12.O'Donnell D.E., Fluge T., Gerken F. et al.Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832–848.
(check this in PDF content)
13
Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.
(check this in PDF content)
14
Decramer M., Celli B., Kesten S. et al.Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–1178.
(check this in PDF content)
15
Troosters T., Celli B., Lystig T. et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur. Respir. J. 2010; 36: 65–73.
(check this in PDF content)
16
Morice A.H., Celli B., Kesten S. et al. COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir. Med. 2010; 104: 1659–1667.
(check this in PDF content)
17
Panos R.J. Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease. Intern. J. COPD 2013; 8: 221–230.
(check this in PDF content)
18
Dalby R.N., Eicher J., Zierenberg B.Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Med. Devices (Auckl.). 2011; 4: 145–155.
(check this in PDF content)
19
Dalby R., Spallek M., Voshaar T. Areview of the development of Respimat Soft Mist Inhaler. Int. J. Pharm. 2004; 283: 1–9.
(check this in PDF content)
20
Noord J.A., Smeets J.J., Creemers J.P. et al.A randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients. Respiration 2000; 67: 672–678.
(check this in PDF content)
21
Longest P.W., Hindle M., Choudhuri S.D., Byron P.R. Numerical simulations of capillary aerosol generation: CFD model development and comparisons with experimental data. Aerosol. Sci. Technol. 2007; 41: 952–973.
(check this in PDF content)
22
Longest P.W., Hindle M., Choudhuri S.D., Xi J. Comparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth-throat geometry. J. Aerosol. Sci. 2008; 39: 572–591.
(check this in PDF content)
23
Newman S.P., Pavia D., Moren F. et al. Deposition of pressurised aerosols in the human respiratory tract. Thorax 1981; 36: 52–55.
(check this in PDF content)
24
Newman S.P. Aerosol deposition considerations in inhalation therapy. Chest 1985; 88 (Suppl. 2): 152S–160S.
(check this in PDF content)
25
Stein S.W., Gabrio B.J. Understanding throat deposition during cascade impactor testing. In: Dalby R.N., Byron P.R., Farr S.J., Peart J., eds. Respiratory drug delivery VII. Serentec, Raleigh, NC; 2000. 573–576.
(check this in PDF content)
26
Longest P.W., Hindle M.Quantitative analysis and design of a spray aerosol inhaler. Part 1: effects of dilution air inlets and flow paths. J. Aerosol. Med. Pulm. Drug Deliv. 2009; 22: 271–283.
(check this in PDF content)
27
Hochrainer D., Holz H., Kreher C. et al.Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J. Aerosol. Med. 2005; 18: 273–282. Авдеев С.Н. Новые возможности использования тиотропия бромида с помощью ингалятора Респимат®
(check this in PDF content)
28
Khachikian D.; VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist Executives. Ipratropium / Albuterol (Combivent®Respimat®) Abbreviated Review. 2012. Available from: http://www.pbm.va.gov/ClinicalGuidance/ Abbreviated Reviews/Ipratropium&albuterol(CombiventRespimat). doc. Accessed February 12, 2013.
(check this in PDF content)
29
Newman S.P., Steed K.P., Reader S.J. et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J. Pharm. Sci. 1996; 85: 960–964.
(check this in PDF content)
30
Newman S.P., Brown J., Steed K.P. et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113: 957–963
(check this in PDF content)
31
Pitcairn G., Reader S., Pavia D., Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J. Aerosol. Med. 2005; 18: 264–272.
(check this in PDF content)
32
Caillaud D., Le Merre C., Martinat Y. et al. A dose-ranging study of tiotropium delivered via Respimat®Soft MistTM Inhaler or HandiHaler® in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2007; 2: 559–565.
(check this in PDF content)
33
Ichinose M., Fujimoto T., Fukuchi Y. Tiotropium 5 mg via Respimat and 18 mg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir. Med. 2010; 104: 228–236.
(check this in PDF content)
34
Hodder R., Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat®Soft Mist™ Inhaler. Int. J. Chron. Obstruct. Pulmon. Dis. 2009; 4: 381–390.
(check this in PDF content)
35
Schurmann W., Schmidtmann S., Moroni P. et al. Respimat® Soft Mist Inhaler versus hydrofluoroalkane metered dose inhaler: Patient preference and satisfaction. Treat. Respir. Med. 2005; 4: 53–61.
(check this in PDF content)
36
Brand P., Hederer B., Austen G. et al. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3: 763–770.
(check this in PDF content)
37
Anderson P. Patient preference for and satisfaction with inhaler devices. Eur. Respir. Rev. 2005; 14: 109–116.
(check this in PDF content)
38
Kozma C.M., Slaton T.L., Monz B.U. et al.Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat. Respir. Med. 2005; 4: 41–52.
(check this in PDF content)
39
Hodder R., Reese P.R., Slaton T. Asthma patients prefer Respimat®Soft Mist™ Inhaler to Turbuhaler®. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 225–232.
(check this in PDF content)
40
Freytag F., Rau&Berger H., Glaab T. et al. Respimat®Soft Mist™ Inhaler preferred to Diskus by patients with COPD and / or asthma. Am. J. Respir. Crit. Care Med. 2007; 175: A639.
(check this in PDF content)
41
Rau&Berger H., Mitfessel H., Glaab T.Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 367–373.
(check this in PDF content)
42
Asakura Y., Nishimura N., Maezawaet K. et al.Effect of Switching Tiotropium HandiHaler to Respimat Soft Mist Inhaler in patients with COPD: The difference of adverse events and usability between Inhaler devices. J. Aerosol. Med. Pulm. Drug Deliv. 2013; 26: 41–45.
(check this in PDF content)
43
ClinicalTrials.gov. 12 week comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat®, placebo and Ipratropium MDI in COPD. NCT00239473. 2010. http://clinicaltrials.gov/ct2/show/ NCT00239473.
(check this in PDF content)
44
ClinicalTrials.gov. 12 week comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat®, placebo and Ipratropium MDI in COPD. NCT00240435. 2010. http://clinicaltrials.gov/ct2/show/ NCT00240435.
(check this in PDF content)
45
ClinicalTrials.gov. Tiotropium/Respimat®one-year study. NCT 00168844. 2010. http:// clinicaltrials.gov/ct2/show/NCT00168844.
(check this in PDF content)
46
ClinicalTrials.gov. Tiotropium / Respimat®one-year study. NCT 00168831. 2010. http:// clinicaltrials.gov/ct2/show/NCT00168831.
(check this in PDF content)
47
ClinicalTrials.gov. Tiotropium / Respimat®one-year study in COPD. NCT00387088. 2010. http://clinicaltrials.gov/ct2/show/ NCT00387088.
(check this in PDF content)
48
Bateman E., Singh D., Smith D. et al. Efficacy and safety of tiotropium Respimat®SMI in COPD in two 1-year randomized studies. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 197–208.
(check this in PDF content)
49
Bateman E.D., Tashkin D., Siafakas N. et al. A one-year trial of tiotropium Respimat®plus usual therapy in COPD patients. Respir. Med. 2010; 104: 1460–1472.
(check this in PDF content)
50
Feifel U., Wallenstein G., Rominger K.&L. et al. Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat®Soft Mist™ Inhaler: findings from two dose-ranging studies in healthy men. Int. J. Chron. Obstruct. Pulm. Dis. 2008; 3: 397–403.
(check this in PDF content)
51
Hodder R., Pavia D., Lee A., Bateman E.Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat®Soft Mist™ Inhaler in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2011; 6: 245–251.
(check this in PDF content)
52
Beasley R. Tiotropium Respimat increases the risk of mortality: pro. Eur. Respir. J. 2013; 42: 584–589.
(check this in PDF content)
53
Bateman E.D. Tiotropium Respimat increases the risk of mortality: con. Eur. Respir. J. 2013; 42: 590–593.
(check this in PDF content)
54
Jenkins C.R., Beasley R.Tiotropium Respimat increases risk of mortality. Thorax 2013; 68: 5–7.
(check this in PDF content)
55
Singh S., Loke Y.K., Enrigh P.L., Furberg C.D.Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and metaanalysis of randomised controlled trials. Br. Med. J. 2011; 342: d3215.
(check this in PDF content)
56
Lipworth B.J., Short P.M. Explaining differential effects of tiotropium on mortality in COPD. Thorax 2013; 68: 589–590.
(check this in PDF content)
57
Sharma A., Hohlfeld J., Cornelissen P. et al. Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat®and tiotropium HandiHaler®in COPD patients. In: Proceeding of ERS congress. 2013: 981s (4631).
(check this in PDF content)
58
Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat Inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369: 1491–1501.
(check this in PDF content)
59
Peters S.P., Kunselman S.J., Icitovic N. et al.Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med 2010; 363: 1715–1726.
(check this in PDF content)
60
Kerstjens H.A.M., Engel M., Dahl R. et al.Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012; 367: 1198–1207. Информация об авторе Авдеев Сергей Николаевич – д. м. н., профессор, руководитель клини-
(check this in PDF content)